FCRL5 and plasma cell myeloma: Bispecific antibodies are drugs that bind to two different antigen sites simultaneously, typically CD3 of T cells and tumor antigens (BCMA/FCRh5/GPRC5D) of the myeloma cells enhancing anti-tumor activity of host immune cells.